SCHEMBL15063285

SCHEMBL15063285

COC(=O)CC(C)CC(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.40
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
ECE1 P42892 3/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
KCNA5 P22460 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CA14 Q9ULX7 2/20 0.32
SLC1A1 P43005 1/20 0.32
CA12 O43570 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
MMP1 P03956 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265822 0.88 TSHR (0.50) TSHRALDH1A1HSD17B10MGAMGAA
SCHEMBL3392036 0.83 ALDH1A1 (0.38) TSHRALDH1A1HSD17B10KDM4ELMNA
Alcohol SCHEMBL28286197 0.81 TSHR (0.43) TSHRALDH1A1HSD17B10MGAMGAA
SCHEMBL27986981 0.81 TSHR (0.41) TSHRALDH1A1HSD17B10MGAMGAA
SCHEMBL148546 0.79 TSHR (0.43) TSHRALDH1A1HSD17B10MGAMGAA
SCHEMBL1262529 0.79
SCHEMBL12158758 0.79 MGAM (0.50) TSHRALDH1A1HSD17B10MGAMGAA
SCHEMBL14532417 0.79 MGAM (0.50) TSHRALDH1A1HSD17B10MGAMGAA
SCHEMBL26765970 0.79
SCHEMBL286783 0.79 TSHR (0.43) TSHRALDH1A1HSD17B10MGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4543439-A2 NRF2 PROTEIN DEGRADERS Ganymede Oncology, Inc. (US) 2025-04-30 EP disclosed
WO-2024006742-A2 NRF2 PROTEIN DEGRADERS DRACEN PHARMACEUTICALS, INC. (US) 2024-01-04 WO disclosed
US-8957233-B2 Method for producing optically active 1,2-bis(dialkylphosphino)benzene derivative NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) 2015-02-17 US disclosed
US-20130172597-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 1,2-BIS(DIALKYLPHOSPHINO)BENZENE DERIVATIVE NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) 2013-07-04 US disclosed
CN-1235898-C Cyclohexenedioxythiochromanoyl derivatives BASF AG (DE) 2006-01-11 CN disclosed
CN-1149200-C 2-[(dihydro)pyrazole-3'-oxymethylene] aniline amide and its preparation and use �����ɷ� 2004-05-12 CN disclosed
CN-1149216-C Tricyclic Benzoylcyclohexanedione Derivatives �����ɷ� 2004-05-12 CN disclosed
CN-1364161-A N-substituted perhydrodiazines BASF AG (DE) 2002-08-14 CN disclosed
CN-1308065-A 2-[(dihydro)pyrazole-3'-oxymethylene] aniline amide and its preparation and use BASF AG (DE) 2001-08-15 CN disclosed
CN-1068313-C Amide of 2- [ (dihydro) pyrazole-3' -oxymethylene ] aniline, preparation method and application thereof BASF AG (DE) 2001-07-11 CN disclosed
CN-1066137-C Alpha-phenylbutenic acid methyl esters BASF AG (DE) 2001-05-23 CN disclosed
CN-1166828-A 2-(4-biphenyl-oxymethlene) anilides, process and intermediate products for preparing the same and their use as pesticides BASF AG (DE) 1997-12-03 CN disclosed
CN-1154692-A Amide of 2- [ (dihydro) pyrazole-3' -oxymethylene ] aniline, preparation method and application thereof BASF AG (DE) 1997-07-16 CN disclosed
CN-1150800-A Alpha-phenylbutenic acid methyl ester BASF AG (DE) 1997-05-28 CN disclosed
CN-1098713-A The ortho-ethenylphenylacetic acid derivatives that replaces BASF AG (DE) 1995-02-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172597-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 1,2-BIS(DIALKYLPHOSPHINO)BENZENE DERIVATIVE RDX, BRIX1, P2RX1 TSHR 1809/4885ALDH1A1 2562/4885HSD17B10 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.